Literature DB >> 8694545

Pattern of mucin gene expression in normal and neoplastic lung tissues.

E Seregni1, C Botti, C Lombardo, A Cantoni, A Bogni, I Cataldo, E Bombardieri.   

Abstract

This work evaluates the expression in lung cancer of the most well characterized mucin genes (MUC1, MUC2, MUC3) and of the recently described MUC4 in lung tissues, to check a correlation between the expression of any particular gene and this tumor. Hybridization with synthetic oligonucleotides obtained from a part of the sequences of MUC1, MUC2, MUC3 and MUC4, was performed on blotted RNA from 18 lung cancer tissue specimens and from 10 normal tissues samples taken, when possible, from the normal lung counterpart. By means of Northern blot analysis MUC1 revealed to be the most expressed mucin gene in lung cancer, followed by MUC4; by contrast, the expression of MUC2 and MUC3 was almost undetectable in all cancer specimens. The intensity of expression of MUC1 and MUC4 was always superior in cancer tissue than in the normal counterpart. As expected, the highest reactivity for MUC1 and MUC4 expression was observed mainly in the adenocarcinoma histotype which is mucin secreting. These findings represent a contribution to the study of mucin gene pattern in lung cancer, and, in particular, indicate that MUC4, in association with the MUC1 gene, seems to be strongly expressed in this neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694545

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Ordered subset analysis identifies loci influencing lung cancer risk on chromosomes 6q and 12q.

Authors:  Shenying Fang; Susan M Pinney; Joan E Bailey-Wilson; Mariza A de Andrade; Yafang Li; Elena Kupert; Ming You; Ann G Schwartz; Ping Yang; Marshall W Anderson; Christopher I Amos
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-10-28       Impact factor: 4.254

2.  MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients.

Authors:  F Guddo; A Giatromanolaki; M I Koukourakis; C Reina; A M Vignola; G Chlouverakis; J Hilkens; K C Gatter; A L Harris; G Bonsignore
Journal:  J Clin Pathol       Date:  1998-09       Impact factor: 3.411

3.  Cons: the confusing mucinous adenocarcinoma classification.

Authors:  Helmut H Popper
Journal:  Transl Lung Cancer Res       Date:  2017-04

4.  Transmembrane mucins as novel therapeutic targets.

Authors:  Pamela E Constantinou; Brian P Danysh; Neeraja Dharmaraj; Daniel D Carson
Journal:  Expert Rev Endocrinol Metab       Date:  2011-11

Review 5.  Muc4/sialomucin complex in the mammary gland and breast cancer.

Authors:  K L Carraway; S A Price-Schiavi; M Komatsu; S Jepson; A Perez; C A Carraway
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

6.  MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients.

Authors:  Dhara M MacDermed; Nikolai N Khodarev; Sean P Pitroda; Darrin C Edwards; Charles A Pelizzari; Lei Huang; Donald W Kufe; Ralph R Weichselbaum
Journal:  BMC Med Genomics       Date:  2010-05-06       Impact factor: 3.063

7.  Clinical associations of mucin 1 in human lung cancer and precancerous lesions.

Authors:  Andreas Saltos; Farah Khalil; Michelle Smith; Jiannong Li; Michael Schell; Scott J Antonia; Jhanelle E Gray
Journal:  Oncotarget       Date:  2018-11-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.